Skip to main content
Equibles
BETRF logo

BETRF · BetterLife Pharma Inc.

Track BETRF — free

Use BETRF with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.22 0.00 (-1.69%) At close · Sep 1
Rebalance outlook locked
Market Cap
$37.19M
Shares
169.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.22 Open$0.21 Day$0.21–0.22 52W close$0.03–0.30 Avg vol 30d109K Short int322K · 0.2% float · 1.0d Short vol59% DataJun 2020–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Jun 26, 2020; bars on opposite sides are not compared.

Up next

FQ3-27 quarter ends
~Oct 31, 2026 Est

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+242.5%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +171%
above
Price vs 50-day avg +19%
above
RSI (14) 50
neutral
MACD trend Negative
52-week position 69%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −14%
trailing
6-month return +402%
trailing
YTD return +574%
this year
Relative strength +389%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of float · ▲ +23.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2 holders — 13F breadth
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 174%
annualized · 1-yr
Max drawdown −63%
past year
ATR 11.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+171% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
50 Neutral
MACD trend
Negative Bearish
52-week position
69% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.19% of float · ▲ +23.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2 holders — 13F breadth
Price context
position in its 52-week range
Range low $0 Now $0 · 69% Range high $0
vs 200-day avg +171% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BETRF
BetterLife Pharma Inc.
this stock
$37.19M +574.4% — — 0.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +20.8% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +6.7% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
2
% held
0.0%
Net QoQ
0 sh
Top holder
Bartlett & Co. LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
321.5K
Days to cover
1.0d
Change
+60.2K sh
View
Short Volume
Short vol %
59%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
17.2K
Value
$3.8K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
CAD -9.1M
EPS diluted
$-1.10
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 24, 2026
This year
6
View

Performance

Raw-price comparisons begin at the captured split on Jun 26, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BETRF -18.7% -13.7% +401.9% -1.7% +574.4%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -18.1% -12.4% +389.2% -1.0% +562.7%
Key facts CIK 1464165 CUSIP 08772P202 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)